Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Feb 2026: Ibex announced a leadership change, with COO Yair Heller becoming CEO and co-founder Joseph Mossel moving to lead its biopharma division and US clinical growth. No lawsuits, regulator action or financial distress found in HSH's search of the last 24 months.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Ibex Medical Analytics found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No recalls, FDA/MHRA safety notices or warning letters involving Ibex Medical Analytics found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
No dated go-lives, troubled implementations, terminations or disputes involving Ibex Medical Analytics found in HSH's search of the last 24 months; Feb 2026 company materials cite deployments with two large European laboratory networks.